Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What is the current market size of the pneumoconiosis industry, and what growth rate is it expected to achieve?
The pneumoconiosis market size has grown strongly in recent years. It will grow from $5.18 billion in 2024 to $5.61 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to growing occupational exposure to coal dust, rising mining activities in unregulated regions, increasing neglect of worker health policies, growing delays in disease diagnosis, and rising cases of untreated respiratory issues.
The pneumoconiosis market size is expected to see strong growth in the next few years. It will grow to $7.62 billion in 2029 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to rising focus on occupational health standards, growing enforcement of dust control regulations, increasing investments in worker safety programs, growing awareness about pneumoconiosis risks, and rising access to early diagnostic services. Major trends in the forecast period include technological advancements in lung imaging, innovations in portable respiratory devices, developments in ai-based disease detection, investment in research and development for dust-related illnesses, and innovations in wearable air quality sensors.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24380&type=smp
What are the major drivers contributing to the growth of the pneumoconiosis market?
The high prevalence rate of smoking expected to propel the growth of the pneumoconiosis market going forward. Smoking is the act of inhaling and exhaling the smoke of burning tobacco, commonly through cigarettes, cigars, or pipes and releases harmful chemicals into the body, affecting the lungs, heart, and overall health. The increasing prevalence rate of smoking is due to rising nicotine dependence and sustained tobacco use among specific age groups. The high prevalence rate of smoking enhances the pneumoconiosis by increasing the incidence of smoking-related lung diseases. For instance, in June 2023, according to The Guardian, a UK-based news organization, in 2022, 11.8% of 14 to 17-year-olds reported vaping, which increased to 14.5% in early 2023. Therefore, the high prevalence rate of smoking is driving the pneumoconiosis market.
Rising Healthcare Expenditures Fueling Growth Of The Market Due To Increased Demand For Advanced Medical Treatments
Rising healthcare expenditures are expected to propel the growth of the pneumoconiosis market. Healthcare expenditures refer to the total amount of money spent on medical services, treatments, and healthcare-related products by individuals, governments, and organizations. Increasing healthcare expenditures are due to the rising prevalence of chronic diseases, which require long-term care and management. Healthcare expenditures support pneumoconiosis treatment by covering the costs of early diagnosis, continuous medical care, respiratory therapy, and access to specialized treatments and medications that help manage symptoms, slow disease progression, and enhance patients’ quality of life. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, total healthcare expenditure grew by 5.6% in nominal terms from 2022 to 2023, showing a notable acceleration compared to the 0.9% increase seen in 2022. Therefore, rising healthcare expenditures will drive the growth of the pneumoconiosis market.
What are the major market segments driving the growth of the pneumoconiosis industry?
The pneumoconiosis market covered in this report is segmented –
1) By Type: Asbestosis, Berylliosis, Byssinosis, Coal Workers Pneumoconiosis, Silicosis, Other Types
2) By Treatment: Medication, Oxygen Therapy, Pulmonary Rehabilitation, Other Treatments
3) By Route Of Administration: Oral, Inhalational, Other Route Of Administrations
4) By Diagnostic Method: Chest X-ray, Computed Tomography Scan, Lungfunction Tests, Bronchoscopy
5) By End Users: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-users
Sub Segments:
1) By Asbestosis: Pleural plaques, Diffuse pleural thickening, Rounded atelectasis, Lung cancer (as asbestos-related), Mesothelioma
2) By Berylliosis: Acute beryllium disease, Chronic beryllium disease (CBD), Hypersensitivity pneumonitis-like response
3) By Byssinosis: Acute byssinosis (early-stage), Chronic byssinosis, Work-related asthma
4) By Coal Workers’ Pneumoconiosis (CWP): Simple CWP, Complicated CWP (Progressive Massive Fibrosis – PMF), Caplan’s syndrome
5) By Silicosis: Acute silicosis, Accelerated silicosis, Chronic silicosis, Silicotuberculosis
6) By Other Types: Talcosis, Siderosis, Stannosis, Baritosis, Hard metal pneumoconiosis
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/pneumoconiosis-global-market-report
What evolving trends are creating new opportunities in the pneumoconiosis market?
Major companies operating in the pneumoconiosis market are focusing on targeted drug development, such as oral small molecule drug, to provide patients with innovative treatment options that improve disease management and enhance quality of life, fostering better outcomes for those suffering from occupational lung diseases. An oral small molecule drug is a medication that is typically made up of low molecular weight compounds that can be taken by mouth, absorbed into the bloodstream, and designed to target specific biological processes or proteins in the body to treat diseases. For instance, in March 2022, Sino Biopharmaceutical Limited, a China-based pharmaceutical company, launched TDI01 suspension, a first-in-class oral small molecule drug targeting ROCK2 for the treatment of pneumoconiosis. This innovative drug, currently undergoing clinical trials, aims to provide a much-needed therapeutic option for the 900,000 pneumoconiosis patients in China, a condition with no effective treatments available.
Who are the key market players contributing to the growth of the pneumoconiosis industry?
Major companies operating in the pneumoconiosis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Gilead Sciences, Eli Lilly and Co., Boehringer Ingelheim, Mylan Pharmaceuticals, Bristol Myers Squibb, Sino Biopharmaceutical Limited, Aurobindo Pharmaceuticals, Hikma Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Veracyte Inc., Fidia Farmaceutici, PharmaMar, Verastem Inc., RS Oncology, Melinta Therapeutics LLC, Lupin
Which regions are leading the growth of the pneumoconiosis market globally?
North America was the largest region in the pneumoconiosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumoconiosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Pneumoconiosis Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24380&type=smp
Need Customized Data On Pneumoconiosis Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24380&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
